marchesini-group-achema-pulse
May 31, 2021

Marchesini Group takes part in Achema Pulse, the digital event that provides a foretaste of 2022’s international show

In the run-up to the next edition of Achema (4-8 April 2022), the industry’s first big international event after the stop imposed by the pandemic, the German show’s organisers have launched the Achema Pulse digital portal. The platform will be online throughout the month of June, with two red-letter dates, the Live Days on 15 and 16 June, when industry players will present the new process and packaging trends.

Marchesini Group, which has already created its virtual showroom on the Achema Pulse website, will be taking part in the Live Days with three presentations to update its customers effectively with the latest innovations in pharmaceutical packaging technology. First up will be Carlo Brogi - Product Manager at Corima, the Marchesini Group brand specialising in aseptic packaging solutions - who will give an Exhibitor Pitch on 15 June (17:45-18:00) to illustrate the company’s work to develop vaccine filling and secondary packaging lines. Since the outbreak of the pandemic, Marchesini Group has revised its production plans to achieve the maximum acceleration in the realisation and shipment of solutions able to fill and package vials and syringes with anti-Covid-19 vaccines. Today, Marchesini’s technologies - advertised through the international Our Battle in a Bottle campaign - are used in the plants of the main vaccine producers worldwide, especially the manufacturers of Sputnik V and AstraZeneca.

The following day, Alessandro Monopoli and Edoardo Ferretti, Marchesini Group Product Manager and Sales Product Manager, will appear live in an Exhibitor Workshop (11:30-12:15) focused on blister packaging technologies. In the afternoon, (17:00-17:30) Simone Albanese, Marchesini Group Area Manager for the UK and Ireland, will present an Exhibitor Panel on the latest vial packaging solutions.
 
The speeches by the Marchesini Group experts will also be an opportunity to survey the initiatives organised by the Group during the pandemic to provide its customers with full support. Key amongst them are the XDAYS - the digital events which offered a rich overview of the Group’s main technologies - and the launch of the XCARE package, which has enabled over 100 machines to be tested remotely thanks to FAT via streaming. The latest project is the EXTRA portal, the new digital platform that will enable clients to watch streamed events and visit the company remotely, for first-hand exploration and discovery of the vast range of Marchesini Group solutions in accordance with their needs.


Sign in and get your free ticket with your voucher code: SFath

Our Battle for a better Future

We are able to provide pharmaceutical companies around the world with the best solutions in the field of aseptic filling, inspection, labelling and packaging of vials and syringes containing vaccines.

Some product lines have already been used in the production of anti-COVID-19 serums: a major Russian biotechnology company, Biocad of Saint Petersburg, is using a Marchesini Group line to produce the Sputnik V vaccine at a rate of 200 vials per minute. And that’s not all. Projects in Latin America are also progressing with the shipping of CMP Phar.ma machines to a Mexican client who will use them in the packaging process for the AstraZeneca vaccine.

Our Battle for a better Future

We are able to provide pharmaceutical companies around the world with the best solutions in the field of aseptic filling, inspection, labelling and packaging of vials and syringes containing vaccines.

Some product lines have already been used in the production of anti-COVID-19 serums: a major Russian biotechnology company, Biocad of Saint Petersburg, is using a Marchesini Group line to produce the Sputnik V vaccine at a rate of 200 vials per minute. And that’s not all. Projects in Latin America are also progressing with the shipping of CMP Phar.ma machines to a Mexican client who will use them in the packaging process for the AstraZeneca vaccine.